Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 61 - 80 of about 573 ／ All the affair displays >>

Albumin-Globulin Ratio Indicates the Survival Outcome of Pancreatic Cancer Cases Who Underwent Preoperative Treatment and Curative Surgical Resection. Reviewed International journal

Masamichi Hayashi, Daigo Kobayashi, Hideki Takami, Yoshikuni Inokawa, Nobutake Tanaka, Keisuke Kurimoto, Koki Nakanishi, Shinichi Umeda, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Yasuhiro Kodera

Nutrition and cancer Vol. 75 ( 5 ) page： 1330 - 1339 2023.5

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: The pretreatment albumin-globulin ratio (AGR) is a frequently used inflammation-associated factor that has been reported to have associations with the survival outcomes of various malignancies. METHODS: We retrospectively analyzed 162 patients with pancreatic cancer who underwent preoperative treatment followed by curative surgery at Nagoya University Hospital between April 2010 and December 2020. Representative nutritional status indicators of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and albumin-globulin ratio (AGR) were calculated for each case. RESULTS: Among pretreatment blood examination parameters, only AGR (cutoff: 1.33) showed a significant difference in overall survival time (OS) and progression-free survival time (PFS) from the beginning of the preoperative treatment. Median PFS was 22.3 mo, in high AGR cases and 17.1 mo, in low AGR cases (P = 0.019). Median OS was 48.7 mo, in high AGR cases and 32.9 mo, in low AGR cases (P = 0.043). CONCLUSION: High pretreatment AGR may be a favorable prognostic factor for pancreatic cancer patients who received preoperative multimodal therapy followed by curative cancer resection. It may imply that nutritional status and inflammation control before the multimodal treatment affect the survival outcomes of pancreatic cancer cases and needs to be optimized.

DOI： 10.1080/01635581.2023.2191384

Web of Science

PubMed

A liquid biopsy signature for predicting early recurrence in patients with gastric cancer Reviewed

Okuno Keisuke, Watanabe Shuichi, Roy Souvick, Kanda Mitsuro, Tokunaga Masanori, Kodera Yasuhiro, Kinugasa Yusuke, Goel Ajay

BRITISH JOURNAL OF CANCER Vol. 128 ( 6 ) page： 1105 - 1116 2023.4

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3 Reviewed

Chin Keisho, Yamamoto Shun, Takahashi Masanobu, Kadowaki Shigenori, Kubota Yutaro, Amanuma Yusuke, Okada Morihito, Kanda Mitsuro, Kimura Yasue, Nogi Yuhiko, Arimitsu Yuko, Kitagawa Yuko

ESOPHAGUS Vol. 20 ( 2 ) page： 302 - 308 2023.4

治癒切除不能胃癌におけるconversion surgery対象選択の客観的指標とはなにか? Reviewed

中西香企, 田中千恵, 神田光郎, 宮田一志, 清水大, 杉田静紀, 藤原道隆, 江畑智希, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 123回 page： SF - 5 2023.4

治癒切除不能胃癌におけるconversion surgery対象選択の客観的指標とはなにか? Reviewed

中西香企, 田中千恵, 神田光郎, 宮田一志, 清水大, 杉田静紀, 藤原道隆, 江畑智希, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 123回 page： SF - 5 2023.4

胃癌術後の他病死リスク予測モデルの構築 Reviewed

伊藤雄貴, 三輪高嗣, 神田光郎, 伊藤誠二, 望月能成, 中西香企, 清水大, 田中千恵, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 123回 page： DP - 4 2023.4

膵IPMN切除後予後に関連する因子および術後補助療法の影響に関する検討 Reviewed

猪川祥邦, 高見秀樹, 栗本景介, 田中伸孟, 林真路, 中西香企, 梅田晋一, 清水大, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 123回 page： DP - 5 2023.4

術前血清C reactive proteinとprognostic nutritional indexの組み合わせは大腸癌術後長期予後を予測する Reviewed

梅田晋一, 中山吾郎, 服部憲史, 岸田貴喜, 小倉淳司, 村田悠紀, 中西香企, 清水大, 神田光郎, 田中千恵, 藤原道隆, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 123回 page： SF - 8 2023.4

切除可能・切除可能境界型膵癌に対する腹腔洗浄細胞診の意義と治療戦略 Reviewed

田中伸孟, 高見秀樹, 栗本景介, 林真路, 中西香企, 梅田晋一, 清水大, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小寺泰弘

日本外科学会定期学術集会抄録集 Vol. 123回 page： SF - 4 2023.4

Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer. Reviewed International journal

Yao Liang, Osamu Maeda, Kazushi Miyata, Mitsuro Kanda, Dai Shimizu, Shizuki Sugita, Tohru Okada, Junji Ito, Mariko Kawamura, Shunichi Ishihara, Masahiro Nakatochi, Masahiko Ando, Yasuhiro Kodera, Yuichi Ando

Molecular and clinical oncology Vol. 18 ( 4 ) page： 34 - 34 2023.4

Language：English Publishing type：Research paper (scientific journal)

The present study aimed to assess the feasibility of global standard chemoradiotherapy (CRT) followed by surgery in patients with esophageal cancer. A prospective study was conducted at Nagoya University Hospital (Nagoya, Japan) to evaluate global standard CRT followed by surgery in patients with esophageal cancer. The CRT regimen consisted of 75 mg/m2 cisplatin on day 1 and 1,000 mg/m2 fluorouracil daily on days 1-4 given twice 4 weeks apart together with concurrent esophageal irradiation starting on day 1 (group A). For comparison, 17 patients with esophageal cancer who had received the same chemotherapy regimen but with lower drug doses were retrospectively reviewed: 70 mg/m2 cisplatin on day 1 and 700 mg/m2 fluorouracil daily on days 1-4 given twice 4 weeks apart together with concurrent esophageal irradiation starting on day 1 (group B). Grade 3 or worse adverse events were observed in 9 of the 12 patients (75%) in group A and in 5 of the 17 patients (29%) in group B. The patients in group A were more likely to experience grade 3 or worse neutropenia (50%) than those in group B (6%). No febrile neutropenia or treatment-related deaths occurred in either group. A total of 11 patients (92%) in group A and 16 patients (94%) in group B subsequently underwent an esophagectomy, and 9 (82%) and 14 (88%) of these patients, respectively, achieved microscopically margin-negative resection (R0 resection). In conclusion, global standard CRT was more likely to cause severe but manageable adverse events. There was no apparent difference in the R0 resection rate or postoperative complications between the two treatments. This clinical trial was registered at the Japan Registry of Clinical Trials (trial registration number: jRCT1041180004) on September 11, 2018.

DOI： 10.3892/mco.2023.2630

Web of Science

PubMed

Modified Albumin-Bilirubin Grade optimized for risk stratification of patients with stage II-III gastric cancer. Reviewed

Michita Shoka, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Dai Shimizu, Chie Tanaka, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Surgery today 2023.3

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: The albumin-bilirubin (ALBI) grade is calculated using albumin and bilirubin values. We determined the optimal cutoff value of the ALBI grade for predicting the postoperative prognosis of gastric cancer (GC). METHODS: We retrospectively reviewed a multicenter database of 3571 patients who underwent gastrectomy for GC between January 2010 and December 2014. The modified ALBI (mALBI) grade was determined using cutoff values: grade 1 (mALBI ≤ - 2.70), 2 (mALBI - 2.70 to - 2.10), and 3 (mALBI > - 2.10). We used a validation cohort to evaluate reproducibility. RESULTS: The entire cohort (n = 956) was randomly assigned to the learning or validation cohorts (n = 478 each). The former was categorized into the following groups by the preoperative mALBI grade: grade 1 (n = 235), grade 2 (n = 162), and grade 3 (n = 81). The disease-specific survival (DSS) rates of the learning and validation cohorts were significantly shortened in association with higher mALBI grade (learning, p = 0.0068; validation, p = 0.0100). A multivariate analysis revealed that mALBI grade 3 served as an independent prognostic factor for DSS. Furthermore, mALBI grade 2 or 3 was associated with a greater risk of disease-specific death in most subgroups. CONCLUSION: The mALBI grade accurately predicted the long-term postoperative prognosis of locally advanced GC.

DOI： 10.1007/s00595-023-02669-x

Web of Science

PubMed

Risk score for predicting death from other causes after curative gastrectomy for gastric cancer. Reviewed

Yuki Ito, Takashi Miwa, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Chie Tanaka, Daisuke Kobayashi, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Vol. 26 ( 2 ) page： 317 - 323 2023.3

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: The number of patients who die from causes other than gastric cancer after R0 resection is increasing in Japan, due in part to the aging population. However, few studies have comprehensively investigated the clinicopathological risks associated with deaths from other causes after gastrectomy. This study aimed to build a risk score for predicting such deaths. METHODS: We retrospectively reviewed clinical data for 3575 patients who underwent gastrectomy for gastric cancer at nine institutions in Japan between January 2010 and December 2014. RESULTS: The final study population of 1758 patients were assigned to Group A (n = 187): patients who died from other causes within 5 years of surgery, and Group B (n = 1571): patients who survived ≥ 5 years after surgery. Multivariate analysis identified nine characteristics as risk factors for poor survival: age ≥ 75 years, male sex, body mass index < 22 kg/m2, Eastern Cooperative Oncology Group Performance Status (≥ 1), diabetes mellitus, cardiovascular/cerebrovascular disease, other malignant diseases, preoperative albumin level < 3.5 g/dL, and total gastrectomy. Patients with risk scores of 0-2, 3-4, or 5-9 (based on 1 point per characteristics) were classified into Low-risk, Intermediate-risk, and High-risk groups, respectively. The 5-year survival rates were 96.5%, 85.3%, and 56.5%, for the Low-, Intermediate-, and High-risk groups, respectively, and the hazard ratio (95% confidence intervals) was 16.33 (10.85-24.58, p < 0.001) for the High-risk group. CONCLUSIONS: The risk score defined here may be useful for predicting deaths from other causes after curative gastrectomy.

DOI： 10.1007/s10120-022-01354-1

Web of Science

PubMed

Combined intraperitoneal and systemic chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer: PHOENIX-GC2 trial. Reviewed

Ishigami, H; Omori, T; Tsuji, Y; Shinohara, H; Yabusaki, H; Kobayashi, D; Takahari, D; Hata, H; Kusumoto, T; Kanda, M; Oba, K; Kitayama, J; Seto, Y

JOURNAL OF CLINICAL ONCOLOGY Vol. 41 page： TPS477 - TPS477 2023.2

Proposal of a coagulation score to predict postoperative survival of patients undergoing neoadjuvant therapy followed by subtotal esophagectomy for squamous cell carcinoma of the esophagus. Reviewed

Sugiyama, F; Shimizu, D; Kanda, M; Tanaka, C; Takami, H; Inokawa, Y; Hattori, N; Hayashi, M; Nakayama, G; Fujiwara, M; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY Vol. 41 page： 448 - 448 2023.2

Perioperative changes in geriatric functions of elderly patients undergoing surgical resection for gastric cancer. Reviewed

Tanaka, C; Kanda, M; Nakanishi, K; Umeda, S; Shimizu, D; Inokawa, Y; Takami, H; Hayashi, M; Nakayama, G; Fujiwara, M; Kodera, Y; Hattori, N

JOURNAL OF CLINICAL ONCOLOGY Vol. 41 page： 811 - 811 2023.2

Preoperative neutrophil-to-platelet ratio as a potential prognostic factor for gastric cancer with positive peritoneal lavage cytology in the absence of other non-curative factors: a multi-institutional dataset analysis. Reviewed

Akira Nonogaki, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Chie Tanaka, Daisuke Kobayashi, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Surgery today Vol. 53 ( 2 ) page： 198 - 206 2023.2

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: Peritoneal dissemination is the key to the prognosis of gastric cancer (GC) and can be detected early with peritoneal lavage cytology. No studies have examined preoperative prognostic factors in GC patients who have positive cytology but no other non-curative factors. METHODS: We conducted a retrospective analysis using a multicenter database of 3575 patients who underwent gastrectomy between 2010 and 2014. Patients with positive peritoneal lavage cytology as a sole non-curative factor were retrieved, and correlations between parameters and the prognosis were compared. RESULTS: A total of 66 patients were identified as eligible. In the receiver operating characteristic (ROC) curve analysis, the neutrophil-to-platelet ratio (NPR) had the greatest area under the curve value and was selected. We divided the NPR into two groups based on the optimal cutoff value of the NPR (2.000), as determined by the ROC curve analysis. A high preoperative NPR was the only prognostic factor. The NPR-high group had shorter overall survival than the NPR-low group (hazard ratio 1.85, 95% confidence interval 1.05-3.28, P = 0.032). CONCLUSION: Our analysis indicated that the preoperative NPR serves as a prognostic factor in GC patients with positive peritoneal lavage cytology in the absence of other non-curative factors.

DOI： 10.1007/s00595-022-02539-y

Web of Science

PubMed

胃癌術後5年以内の他病死リスク予測モデルの構築 Reviewed

伊藤雄貴, 三輪高嗣, 神田光郎, 伊藤誠二, 望月能成, 中西香企, 清水大, 田中千恵, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 95回 page： 443 - 443 2023.2

胃癌術後肺転移に対する手術の治療成績 Reviewed

野々垣彰, 中西香企, 田中千恵, 神田光郎, 清水大, 猪川祥邦, 服部憲史, 中山吾郎, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 95回 page： 323 - 323 2023.2

薬物療法の新展開胃癌転移制御を目指した創薬研究の展開 Reviewed

神田光郎, 田中千恵, 清水大, 中西香企, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 中山吾郎, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 95回 page： 164 - 164 2023.2

進行胃癌に対しての腹腔鏡下胃切除術の注意点と短期成績 Reviewed

杉田静紀, 宮田一志, 田中千恵, 神田光郎, 中西香企, 小寺泰弘, 江畑智希

日本胃癌学会総会記事 Vol. 95回 page： 345 - 345 2023.2

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro